AviadoBio Expands Presence at Canary Wharf – 18.04.24

• The pioneering gene therapy company is consolidating its UK office and lab space to form a central innovation hub at 20 Water Street

AviadoBio, a pioneering gene therapy company dedicated to developing and delivering transformative medicines for neurodegenerative disorders, is expanding its presence at Canary Wharf.  

In addition to its space at Kadans Science Partner’s (“Kadans”) London Innovation Centre at 20 Water Street, AviadoBio will also now lease 11,000 sq ft on level six of 20 Water Street. This leasing further expands the growing life sciences cluster being developed at Canary Wharf by Kadans and Canary Wharf Group (CWG). 

AviadoBio’s Chemistry, Manufacturing and Controls (CMC) team initially leased space at the London Innovation Centre at 20 Water Street in November 2023 and the company is now moving to 11,000 sq ft of laboratory and office space within the same building to accommodate its growing team and its efforts developing and delivering transformative gene therapies for diseases such as frontotemporal dementia. 

This expansion will allow AviadoBio to bring its 60-strong team together under one roof, while providing space for the life science company to continue to grow, as well as build on its ambitions of nurturing breakthrough discoveries. 

The London Innovation Centre, which was launched by Kadans in June 2023, comprises 40,000 sq ft of fully fitted, flexible or bespoke wet-labs, ranging in size from 250 sq ft to over 2,000 sq ft, with tenants able to rent a single bench in a shared lab, or take their own private facility.  

AviadoBio has been one of many companies taking advantage of a wide range of ancillary amenities including private or shared office accommodation, meeting rooms and a boardroom, collaboration space and breakout areas, and kitchen facilities at Kadans’ London Innovation Centre. The company will now move into a bespoke space with all the amenities required for its development activities. 

20 Water Street forms part of the growing life sciences community at Canary Wharf, which also includes Kadans’ and CWG’s development of an 823,000 sq ft GIA commercial health and life sciences building on the 3.3-hectare North Quay site, which is expected to be complete in 2027. 

Lisa Deschamps, CEO of AviadoBio, said: “Since moving into our state-of-the-art space at the London Innovation Centre we have been able to continue important work developing our programmes and pipeline, while being surrounded by others within the life science community. Having seen what Canary Wharf offers growing life sciences companies we felt it was the right time for us to consolidate our UK lab and office space into one central hub here in Canary Wharf. It provides everything we need to be able to continue working on projects that will transform the lives of patients living with neurodegenerative disorders and allows us room to grow as we expand our business.”  

James Sheppard, Head of International Asset Management at Kadans Science Partner, added: “Working in tandem with CWG, we have experienced real momentum through leasing success and welcomed new life science companies such as AviadoBio, IMU Biosciences, Plasmidsaurus, Lab Med Expert and Clustermarket to our London Innovation Centre. We’re now excited to continue providing start-up, early-stage and more mature companies much-needed space where they can grow with us at Canary Wharf.” 

Shobi Khan, CEO of Canary Wharf Group, said: “It is testament to the high-quality facilities available at 20 Water Street and the supportive life science community we are fostering at Canary Wharf that companies, such as AviadoBio, want to increase their presence here.  

“Four years ago, we launched Canary Wharf 3.0 to provide a greater variety of amenities, biodiversity and green space across the Wharf. It also set out our ambition to make the area home to Europe’s leading life sciences community. With AviadoBio expanding amongst a host of life sciences and healthcare organisations already based at Canary Wharf such as Genomics England, Barts Health NHS Trust and hVIVO, we are well on our way in achieving this.” 

ENDS 

For more information contact: 
Richard Sunderland, Richard Stocks, Ciara Martin 
FTI Consulting 
Canarywharf@fticonsulting.com 
+44 (0)20 3727 1000